Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Analysis — Probabli.AI
AI-powered analysis for TNXP (Tonix Pharmaceuticals Holding Corp.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Neutral.
Last price: $13.98 · Market cap: $198.6M · AI outlook: Neutral
Tonix Pharmaceuticals represents a high-risk, high-reward investment in the volatile biotech space. While recent positive news improves the potential for upside scenarios, significant financial and operational risks persist. Future performance hinges on clinical trial success, regulatory approvals, and the ability to secure non-dilutive funding.
Probabilistic 1-Year Outlook
- Bull 40% · Neutral 35% · Bear 25%
- 1-year price estimates — P10: $9 / P50: $17 / P90: $25
- Tonix Pharmaceuticals has a volatile profile driven by its developmental pipeline and recent positive news; however, its high cash burn rate and recent trial failures pose significant risks.
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $10 / P50: $25 / P90: $60
SWOT Highlights
- Strength: Innovative pharmaceutical pipeline
- Strength: Recent positive trial results for PTSD treatment
- Risk: Consistent financial losses
- Risk: Analyst mean and median price targets are lower than current price
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
4 Wall Street analysts rate TNXP a HOLD with a mean price target of $2.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
TNXP forecast details · TNXP sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.